Jens Baas, CEO of the Techniker Krankenkasse, has strongly criticized the coalition government concerning the ongoing dispute over the health savings package. Baas accused the black-and-red governing coalition of appeasing the pharmaceutical industry, suggesting the political parties are easily swayed by corporate threats. Speaking to “Redaktionsnetzwerk Deutschland” Baas stated, “The government must not allow itself to be blackmailed by the pharmaceutical industry” adding that “politics underestimates its own power and overestimates that of the pharmaceutical corporations”. He pointed out that even in the United States, a massive market where President Donald Trump applies intense pressure on manufacturers, no corporation has withdrawn. Consequently, he urged that the pharmaceutical industry’s contribution to savings must be significantly increased during parliamentary discussions.
The CEO also sharply dismissed the industry’s common arguments. When the pharma lobby repeatedly claims a direct link between the decision to research and produce goods in a particular country and the resulting drug prices, Baas called this “nonsense”. He questioned the credibility of the industry’s threat to withdraw certain medications from the German market if prices were set too low. Baas countered this by reminding the public that Germany already has some of the highest drug prices globally, arguing that no major pharmaceutical corporation could afford to abandon one of the world’s most interesting markets.
Furthermore, Baas voiced criticism regarding the coalition’s internal debate surrounding a reduction in the number of sickness funds. He viewed the discussion as a political distraction, predicting that any achievable savings effect would be marginal at best. According to him, the majority of staff at a health insurance fund deal with concrete issues for policyholders, making staff reductions difficult. He specifically criticized the proposed salary cap for administrative executives as counterproductive. Baas emphasized that health insurance funds require highly qualified staff because they must negotiate effectively with various powerful stakeholders-including doctors, hospitals, and the pharmaceutical industry. He concluded that “only top-tier qualified personnel can secure the best outcomes for the contribution payers in such negotiations”.
